Status:
COMPLETED
Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES Databases
Lead Sponsor:
AstraZeneca
Conditions:
Influenza
Eligibility:
All Genders
Up to 17 years
Brief Summary
In 2013, the NHS started a vaccination program in some regions of England to provide free flu vaccines to children aged 2 years or older, and younger than 16 years. The program has since been rolled o...
Detailed Description
A Live Attenuated Influenza Vaccination (LAIV) has been offered to children through a rolling national program in England since 2013. Previous observational studies identified trends in LAIV uptake th...
Eligibility Criteria
Inclusion
- The reference study cohort will include patients as follows:
- Aged ≥2 and \<18 years at any time between 1 September 2012 and 30 April 2020
- Classified as eligible for inclusion in research analysis according to CPRD guidance
- In each flu season, the following criteria apply:
- Aged ≥6 months and \<2 years on the 1st September
- Have a high-risk condition as listed in the Green Book.
Exclusion
- Were deceased or had migrated out of their practice prior to the 1st September in the current influenza season.
- Were recorded has receiving both QIV and LAIV in the current influenza season.
Key Trial Info
Start Date :
January 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 4 2023
Estimated Enrollment :
12775880 Patients enrolled
Trial Details
Trial ID
NCT06077045
Start Date
January 18 2023
End Date
July 4 2023
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CPRD
London, United Kingdom